Direct Targeting of KRAS-G12X Mutant Cancers with RMC-6236, a First-in-Class, RAS-Selective, Orally Bioavailable, Tri-complex RAS-MULTI(ON) Inhibitor

Elena S. Koltun, Meghan A. Rice, W. Clay Gustafson, David Wildes, Jingjing Jiang, Bianca J. Lee, Zhengping Wang, Stephanie Chang, Mike Flagella, Yunming Mu, Nuntana Dinglasan, Nicole Nasholm, James W. Evans, Yingyun Wang, Kyle Seamon, Yang Liu, Cristina Blaj, John Knox, Rebecca Freilich, Elsa Quintana, Jim Cregg, Alun Bermingham, Adrian L. Gill, Jacqueline A.M. Smith, Mallika Singh

 

American Association for Cancer Research (AACR) Annual Meeting 2022; April 8-13, 2022

 

Return to Media Home